HB1801 Clinical Trials
4 recruitingDrug
Phase 33Phase 21
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Resectable HER2-positive Breast Cancer
Shanghai JMT-Bio Inc.1,800 enrolled1 locationNCT07441460
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmBreast Tumors
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 3
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.880 enrolled1 locationNCT05838066
Recruiting
Phase 3
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
Early or Locally Advanced HER2-positive Breast Cancer
Shanghai JMT-Bio Inc.520 enrolled1 locationNCT06747338